Summary
Azaya Therapeutics Inc Azaya Therapeutics, a subsidiary of Cytori Therapeutics Inc, is a health and fitness advisory service provider. The company's service categories include body building, health and health products. It offers information on various exercises such as jumping jacks, plank, cycling and jogging. Azaya Therapeutics also provides home remedies to treat the warts. The company offers information on health risks of getting a tattoo, which may cause allergic reactions, hepatitis , swelling and burning, burn marks, and dyes. Azaya Therapeutics is headquartered in San Antonio, Texas, the US. Azaya Therapeutics Inc  Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope
Financial Deals  Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year  Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type  Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region  Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector  Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals  Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description  A brief description of the company's operations. Key Employees  A list of the key executives of the company. Important Locations and Subsidiaries  A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors  A list of the key competitors of the company. Key Recent Developments  A brief on recent news about the company. Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy
The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company
Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research
Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

Azaya Therapeutics Inc  Pharmaceuticals  Healthcare  Deals and Alliances Profile Report Updated 08112017 Prices from USD $250

Azaya Therapeutics Inc  Pharmaceuticals  Healthcare  Deals and Alliances Profile [Report Updated: 25072017] Prices from USD $250
20:36 EDT 10 Aug 2017 | BioPortfolio Reports
Home » Topics » Biotechnology » Latest News » Azaya Therapeutics Inc  Pharmaceuticals  Healthcare  Deals and Alliances Profile [Report Updated: 25072017] Prices from USD $250
Summary
Azaya Therapeutics Inc Azaya Therapeutics is a biotechnology company that develops and markets drugs for the treatment of cancer and other conditions. The company offers pipeline products that include ATI1123, a liposomal encapsulated formulation of docetaxel, the active ingredient in Taxotere; and ATI0918, a generic formulation of DOXIL or CAELYX, a liposomal formulation of doxorubicin hydrochloride. It uses Protein Stabilized Liposome, a nanotechnology platform to develop safe and efficient therapies for cancer and other serious medical conditions. The company also offers contract manufacturing services. Azaya Therapeutics is headquartered in San Antonio, Texas, the US. Azaya Therapeutics Inc  Pharmaceuticals  Healthcare  Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope
Financial Deals  Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year  Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type  Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region  Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector  Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals  Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description  A brief description of the company's operations. Key Employees  A list of the key executives of the company. Important Locations and Subsidiaries  A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors  A list of the key competitors of the company. Key Recent Developments  A brief on recent news about the company. Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy
The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company
Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research
Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

Azaya Therapeutics Inc  Pharmaceuticals  Healthcare  Deals and Alliances Profile Report Updated 25072017 Prices from USD $250

XconomyTexas — 
San Antonio — Cytori Therapeutics is in the process of restarting a San Antonio manufacturing facility it gained in February when it acquired Azaya Therapeutics, the maker of nanoparticle-encapsulated generic drugs. The San Diego-based company now plans to find a European distributor for a drug that facility makes. Cytori (NASDAQ: CYTX ) is working to bring the manufacturing staff in San Antonio to about 20 as it validates the capabilities of the site, which will produce Azaya’s drug called ATI-0918, a formulation of generic chemotherapy drug liposomal doxorubicin (marketed as Doxil in the U.S. and Caelyx in Europe). Cytori says the Azaya drug showed in a European clinical trial it was bioequivalent to the chemotherapy, which was one of the reasons Cytori acquired Azaya, according to John Harris, a vice president and general manager at Cytori who oversees the company’s commercial and partnership operations. “We’d be looking for a drug company that has an existing pipeline, and is looking for late-term and existing assets to put into their funnel,” Harris said about making a deal in Europe. A deal may net some cash for Azaya shareholders, who agreed to sell the company for $2 million in Cytori stock in January. The sale also included potential milestone and royalty payments, including one worth up to $50 million if Cytori is able to license or sell the Azaya assets (though a deal in Europe alone almost certainly wouldn’t come close to that $50 million figure). Cytori also wants to gain regulatory approval for ATI-0918 as a generic in the U.S., but it still needs to perform clinical testing to show it is bioequivalent to doxorubicin. Other generic versions of doxorubicin are already available, including Lipodox sold in the U.S. by Sun Pharma. Milestone payments are also be tied to a second Azaya drug, ATI-1123, which is meant to help deliver another widely used chemotherapy, docetaxel. Azaya completed a Phase 1 trial in 2012, and now Cytori will look to start a Phase 2 study, which it may be able to fund using money from a deal for ATI-0918, or it may instead look for outside help, Harris says. The nanoparticle encapsulation is meant to help deliver old chemotherapies and other drugs more safely and effectively. Cytori may try to license ATI-0918 on a regional basis and ATI-1123 globally, Harris says. Cytori, meanwhile, has a separate product line it is also developing in cellular therapy. The company is seeking to gain U.S. approval for its product, called Cytori Cell Therapy, as a medical device to treat scleroderma, a rare, progressive autoimmune disorder that affects blood vessels and organs. It often causes the hands to calcify and contract, causing severe sensitivity to temperature and pain, Harris says. Cytori is waiting for results from a 48-week, 80-patient Phase 3 trial, which it expects later this year. The device uses a patient’s own fat tissue, typically taken through liposuction, Harris says. The tissue is put in the closed system, which separates the fat from a “cocktail of cells including stem cells,” and the cells are then reinserted into the patient, Harris says. Cytori is also studying the cellular therapy in knee osteoarthritis and a type of urinary incontinence. It makes a small amount of direct sales in Japan already for knee osteoarthritis and breast reconstruction, due to that country’s laws regarding cell therapy, Harris says. Azaya constructed the San Antonio manufacturing facility but then suspended its business in 2015 after a deal to sell to Lake Forest, IL-based Hospira (NYSE: HSP ) fell through, Azaya’s chairman and co-founder John Kerr told Xconomy earlier this year . Cytori came into play after a second deal also didn’t materialize. Harris says Cytori may consider adding new capabilities to the San Antonio site, including a clinical chemistry lab and, possibly at some point, some of Cytori’s own product manufacturing. David Holley is Xconomy's national correspondent based in Austin, TX. You can reach him at dholley@xconomy.com Follow @xconholley

Cytori Reboots Azaya Facility After Buyout, Looks for European Deal

View More Jobs
Xconomy Texas — San Antonio — Cytori Therapeutics is in the process of restarting a San Antonio manufacturing facility it gained in February when it acquired Azaya Therapeutics, the maker of nanoparticle-encapsulated generic drugs. The San Diego-based company now plans to find a European distributor for a drug that facility makes. Cytori is working to bring the manufacturing staff in San Antonio to about 20 as it validates the capabilities of the site, which will produce Azaya’s drug called ATI-0918, a formulation of generic chemotherapy drug liposomal doxorubicin (marketed as Doxil in the U.S. and Caelyx in Europe).

Cytori Restarting Texas Facility it Inherited From Azaya Therapeutics Buyout Deal

Azaya Therapeutics Inc  Pharmaceuticals  Healthcare  Deals and Alliances Profile [Updated: 23032017] Prices from USD $250
18:09 EDT 22 Apr 2017 | BioPortfolio Reports
Home » Topics » Bioscience » Latest News » Azaya Therapeutics Inc  Pharmaceuticals  Healthcare  Deals and Alliances Profile [Updated: 23032017] Prices from USD $250
Summary
Azaya Therapeutics Inc Azaya Therapeutics is a biotechnology company that develops and markets drugs for the treatment of cancer and other conditions. The company offers pipeline products that include ATI1123, a liposomal encapsulated formulation of docetaxel, the active ingredient in Taxotere; and ATI0918, a generic formulation of DOXIL or CAELYX, a liposomal formulation of doxorubicin hydrochloride. It uses Protein Stabilized Liposome, a nanotechnology platform to develop safe and efficient therapies for cancer and other serious medical conditions. The company also offers contract manufacturing services. Azaya Therapeutics is headquartered in San Antonio, Texas, the US. Azaya Therapeutics Inc  Pharmaceuticals  Healthcare  Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope
Financial Deals  Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year  Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type  Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region  Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector  Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals  Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description  A brief description of the company's operations. Key Employees  A list of the key executives of the company. Important Locations and Subsidiaries  A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors  A list of the key competitors of the company. Key Recent Developments  A brief on recent news about the company. Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy
The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company
Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research
Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

Azaya Therapeutics Inc  Pharmaceuticals  Healthcare  Deals and Alliances Profile Updated 23032017 Prices from USD $250

University of Chicago is a private, non-denominational co-educational research university. It offers educational programs on computational analysis and public policy, law, social work, and more. It was founded in 1890 and is based in Chicago, Illinois.

University of Chicago

Azaya Therapeutics , Inc. , a clinical-stage oncology company developing safer and more effective cancer treatments through its nanotechnology platform , announced a collaboration with the University of Chicago , in Chicago , Illinois .

Azaya Therapeutics Collaborates with University of Chicago in Combination Study in Animals

Grant

Azaya is a nanotherapy company utilizing a patented drug delivery technology platform. The tumor-targeted technology aims to allow the company to reformulate marketed chemotherapy drugs to increase their safety and effectiveness.

Azaya Therapeutics

Texas Emerging Technology Fund

Other Investors

Travanti offers transdermal delivery of drugs and cosmetic agents utilizing active-patch technology.

Travanti

Prolog Ventures

Chiasma (NASDAQ: CHMA) is a biopharmaceutical company dedicated to improving the lives of patients with rare diseases by developing and commercializing oral medications that were previously available by injection only.

Lonza Pharma and Biotech is a provider of contract development and manufacturing services that enable pharma and biotech companies to bring medicines to patients in need. From the building blocks of life to the final drug product, its solutions are created to simplify the client's outsourcing experience.

Wells Fargo Success Story

Professional Services

Platform Overview

Compare Azaya Therapeutics vs Travanti

Customers evaluate the quality of Azaya Therapeutics's products using the following success metrics.